Anocca

Executive Summary

Anocca is a Swedish biotechnology company pioneering precision T-cell immunotherapies for hard-to-treat cancers. Founded in 2014, the company leverages a unique approach that integrates T-cell biology, advanced biotechnologies, and proprietary software to engineer TCR-T cell therapies. By targeting intracellular antigens presented by HLA molecules, Anocca's platform aims to address a broader range of cancers, including those with low mutational burden or resistance to checkpoint inhibitors. The company's pipeline is preclinical, focusing on solid tumors with high unmet medical need. Although specific financial details and stage are undisclosed, Anocca's differentiated technology and strategic location in Stockholm's vibrant biotech ecosystem position it as a notable player in the cell therapy space. The company remains private, with no disclosed valuation or funding rounds, but its innovative approach has the potential to overcome key limitations of current CAR-T therapies, such as antigen escape and limited solid tumor efficacy. Validation from academic collaborations or early preclinical data could drive significant value.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND-enabling studies completion or FDA filing40% success
• Q3 2026Preclinical efficacy data presentation at major oncology conference50% success
• Q2 2026Series B financing or strategic partnership announcement60% success